Navigation Links
Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
Date:4/17/2008

SEATTLE, April 17 /PRNewswire/ -- The state's Life Sciences Discovery fund has awarded $2.2 million to establish a formal phase 1 clinical-trials program to test new therapies for solid tumors at Fred Hutchinson Cancer Research Center. Announced this evening, the grant is among the first funded by Washington's $350 million tobacco-lawsuit-settlement bonus.

Developing novel therapies targeted to treat solid tumors, in collaboration with local biotechnology and pharmaceutical firms, is the goal of the Hutchinson Center/University of Washington Cancer Consortium. Phase 1 trials are by definition the first testing of cancer therapies in humans. The purpose is to determine whether and how a drug works.

Traditionally, phase 1 studies have been primarily concerned with drug safety. However, with the increased knowledge of the molecular pathways involved in cancer development, an ever-increasing proportion of drugs initially tested in humans prove to be effective, even in the first patients treated.

"Phase 1 trials are critically important, require a high level of unique competencies and, if done correctly, can substantially speed the development of new therapies," said Martin (Mac) Cheever, M.D., director of solid-tumor research at the Hutchinson Center. "This is an outcome that can benefit the state's patients, industry and health care enterprises."

Initially, the program will use the funding to develop a highly efficient infrastructure for implementing early phase -- primarily industry sponsored -- cancer clinical trials, and to provide exploratory funds that will allow Consortium researchers to apply their expertise in cancer imaging and biomarkers to cancer drug development.

The program will be led by John Thompson, M.D., as director of the Consortium phase 1 program. Thompson will be responsible for scientific direction and facilitating new industry and other trial sponsorships.

"Standard therapy for cancer is clearly inadequate," Cheever said. "The best hope is the development of new targeted therapies. Thanks to ever-advancing technologies and expanding basic knowledge of cancer biology -- areas of exceptional strength in the consortium -- the opportunities for developing new therapies targeted to cancer cells have never been greater."

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

About the Life Sciences Discovery Fund

The Life Sciences Discovery Fund, a Washington State agency established in May 2005, makes grant investments in innovative life sciences research to benefit Washington and its citizens. For more information on the Life Sciences Discovery Fund, visit: http://www.lsdfa.org.

CONTACT

Dean Forbes

206-605-0311

dforbes@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cardiac Science to Present at the UBS Global Life Sciences Conference
8. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
9. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. Clarient to Present at the UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: